LAS VEGAS--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announces that new data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback